炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！

Swipe Left For English News

1

遵循PSCI原则，共促价值链的可持续和负责任发展

2

凭借构建可持续供应链的卓越领导力获得奖项认可

3

引领绿色生物药发展，技术创新赋能健康未来

上海,

2025年1月15日

全球领先的合同研究、开发和生产（CRDMO）服务公司药明生物（WuXi Biologics, 2269.HK）宣布，公司已正式加入“制药供应链倡议组织（PSCI）”，成为其供应商合作伙伴。这一举措体现了公司对诚信运营、卓越质量和可靠性的坚定承诺，并彰显了其致力于推动构建负责任供应链实践的决心。

PSCI 是全球制药和医疗健康领域的领先协会，其核心使命是携手合作伙伴推动负责任价值链构建，实现安全、环境和社会效益方面的卓越表现。药明生物在道德、劳工与人权、健康与安全、环境和管理体系等维度秉承PSCI所倡导的负责任供应链原则，更将PSCI原则深度融入供应链管理体系，积极携手全球供应链伙伴推进并实施行业最佳实践，旨在为行业带来广泛而深远的积极影响。

陈智胜

博士

药明生物首席执行官

ESG委员会主席

包容、负责任且极具韧性的供应链是我们业务制胜未来的关键。我们很高兴成为PSCI的一员，共同倡导在价值链上推广并践行负责任的商业行为。展望未来，我们将持续追求杰出的环境、社会和治理（ESG）表现，并赋能全球合作伙伴，推动其迈向ESG发展新高度。

近期，药明生物在2024年香港ESG报告大奖中荣获“可持续供应链领导力奖”。公司致力于和同样坚守高道德标准的合作伙伴共同优化商业实践，驱动行业发展。为践行这一承诺，公司制定了可持续供应链政策，设定了明确目标，并规划详尽路线，定期开展遵循PSCI原则的审计，为供应链伙伴提供专业培训课程，同时积极探索能力建设项目。这些前瞻性举措将引领公司稳步构建更加透明、高道德标准且负责任的供应链体系。

2024年，药明生物凭借领先的绿色生物药解决方案（Green CRDMO），成功入选联合国全球契约组织（UNGC）“‘二十年二十佳’企业可持续发展案例”报告。此外，公司连续两年获得明晟（MSCI）最高AAA ESG评级；连续两年入选道琼斯可持续发展指数（DJSI）；获得国际权威企业可持续发展评估机构EcoVadis“铂金”奖牌；获评晨星Sustainalytics“行业最高评级”和“区域（亚太）最高评级”企业；跻身CDP水安全“A级榜单”并获得CDP气候变化领导力级别评分A-；入选富时社会责任指数系列；入选恒生ESG 50指数，充分彰显了公司在可持续发展领域的卓越表现。

关于药明生物

药明生物（股票代码：2269.HK）是一家全球领先的合同研究、开发和生产（CRDMO）公司。公司通过开放式、一体化生物制药能力和技术赋能平台，提供全方位的端到端服务，帮助合作伙伴发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。

药明生物在中国、美国、爱尔兰、德国和新加坡拥有超过12000名员工。通过药明生物的专业服务团队，以及先进技术和精深洞见，公司为客户提供高效经济的生物药解决方案。截至2024年6月底，药明生物帮助客户研发和生产的综合项目高达742个，其中包括16个商业化生产项目（不包括新冠项目和非活跃项目）。

药明生物将环境、社会和治理（ESG）视为业务发展和企业精神的重要组成部分，并致力于成为全球生物药CRDMO领域的ESG领导者，例如应用更绿色环保的新一代生物制药技术和能源等引领行业发展。公司成立了由首席执行官领导的ESG委员会，全面落实ESG战略并践行可持续性发展承诺。更多信息，请访问：www.wuxibiologics.com。

ESG        

esg@wuxibiologics.com

媒体关系  

PR@wuxibiologics.com

WuXi Biologics Commits to PSCI and Receives Award for Sustainable Supply Chain Leadership

1

Committed to PSCI principles to promote a responsible supply chain 

2

Recognized for sustainable supply chain leadership 

3

As a leading Green CRDMO, driven by innovation for a healthier future 

Shanghai,

January 15, 2025

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has joined the Pharmaceutical Supply Chain Initiative (PSCI) as a Supplier Partner, demonstrating its strong commitment to integrity, quality, reliability, and the advancement of responsible supply chain practices.

PSCI is the leading association for pharmaceutical and healthcare companies with a common vision of excellence in safety, environmental, and social outcomes across the global healthcare value chain. WuXi Biologics fully upholds PSCI principles for responsible supply chain practices in the areas of Ethics, Human Rights and Labor, Health and Safety, Environment, and Management Systems. The company embeds PSCI principles into its own supply chain management system, actively engaging and collaborating with global suppliers to drive best practices and generate positive impacts.

Dr. Chris Chen

Chief Executive Officer

Chairman of the ESG Committee

WuXi Biologics

An inclusive, responsible, and resilient supply chain is key to our long-term business success, and we are pleased to join PSCI in advocating for responsible practices throughout the value chain. We will continuously deliver our own ESG excellence and enable our partners worldwide to fulfill their ESG commitments.

WuXi Biologics was recognized by the 2024 Hong Kong ESG Reporting Awards with a Sustainable Supply Chain Leadership Award for its outstanding performance. The company strives to conduct business with partners who share the same commitment to high ethical and sustainability standards. To create a more transparent, ethical, and responsible supply chain, WuXi Biologics formulates sustainable supply chain policies, sets tangible targets, develops refined roadmaps, performs regular PSCI audits, provides training courses, and explores capacity-building programs.

In 2024, WuXi Biologics was included in the UNGC 20 Case Examples of Sustainable Development for 20 Years Collection for its world-leading green biologics solutions. The company was granted an MSCI AAA Rating and included in Dow Jones Sustainability Indices for two consecutive years; awarded the distinguished Platinum Medal by EcoVadis; recognized as an Industry and Regional ESG Top-Rated Company by Sustainalytics; named to the CDP Water Security "A list" and awarded an "A-" CDP Climate Change score; selected as a Constituent of FTSE4Good Index Series; and listed in the Hang Seng ESG 50 Index.

About 

WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2024, WuXi Biologics is supporting 742 integrated client projects, including 16 in commercial manufacturing (excluding COVID CMO and  non-COVID dormant CMO projects).

WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com

海量资讯、精准解读，尽在新浪财经APP